Armored RNA^® and Armored DNA^™ technologies stabilize and protect nucleic acids from nuclease degradation by packaging them in a protective protein coat. Armored reagents deliver several end-user benefits, including:

Optimized Workflow

Armored RNA, Armored RNA Quant and Armored DNA Quant controls can be added directly to human matrices as an exogenous internal control for extraction with most nucleic acid isolation methods and detection in molecular assays.

Flexibility

Nuclease-resistant protein coat can also be removed by heat lysis for direct detection as a positive run control. For Armored RNA Quant and Armored DNA Quant, analytical quantification is performed with a validated method referencing a NIST-traceable phosphate standard.

Download our Molecular Quality Controls Catalog

Catalog of Armored RNA and Armored DNA Products

Armored RNA Quant^®

Each control encodes in vitro transcribed RNA encapsulated in a protective protein coat to create a virus-like particle resistant to nuclease degradation.

SARS-CoV-2

Description	Part #	Configuration
Targets the Nucleocapsid 1 and Nucleocapsid 2 regions of the CDC recommended Diagnostic Panel (CDC-006-00019).	52151	1x10⁶ cp/mL 250μL

SARS-CoV-2 Sequence

Target	Size	Sequence
N1N2	1105	GAACAAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAAC CAGAATGGAGAACGCAGTGGGGCGCGATCAAAACAACGTCGGCCCCAAGGTTTACCCAATAATACTGCGTCTTGGTTCACCGCTCTCACTCA ACATGGCAAGGAAGACCTTAAATTCCCTCGAGGACAAGGCGTTCCAATTAACACCAATAGCAGTCCAGATGACCAAATTGGCTACTACCGAA GAGCTACCAGACGAATTCGTGGTGGTGACGGTAAAATGAAAGATCTCAGTCCAAGATGGTATTTCTACTACCTAGGAACTGGGCCAGAAGCTG GACTTCCCTATGGTGCTAACAAAGACGGCATCATATGGGTTGCAACTGAGGGAGCCTTGAATACACCAAAAGATCACATTGGCACCCGCAATCC TGCTAACAATGCTGCAATCGTGCTACAACTTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAGAAGGGAGCAGAGGCGGCAGTCAAGC CTCTTCTCGTTCCTCATCACGTAGTCGCAACAGTTCAAGAAATTCAACTCCAGGCAGCAGTAGGGGAACTTCTCCTGCTAGAATGGCTGGCAAT GGCGGTGATGCTGCTCTTGCTTTGCTGCTGCTTGACAGATTGAACCAGCTTGAGAGCAAAATGTCTGGTAAAGGCCAACAACAACAAGGCCAA ACTGTCACTAAGAAATCTGCTGCTGAGGCTTCTAAGAAGCCTCGGCAAAAACGTACTGCCACTAAAGCATACAATGTAACACAAGCTTTCGGCA GACGTGGTCCAGAACAAACCCAAGGAAATTTTGGGGACCAGGAACTAATCAGACAAGGAACTGATTACAAACATTGGCCGCAAATTGCACAAT TTGCCCCCAGCGCTTCAGCGTTCTTCGGAATGTCGCGCATTGGCATGGAAGTCACACCTTCGGGAACGTG

Download Armored RNA Quant^® SARS-CoV-2 PDF

SARS-CoV-2 Panel

Description	Part #	Configuration
Contains multiple regions of SARS-Cov-2 genome including nucleocapsid, envelope, RNA-dependent RNA polymerase, open reading frame 1, and human RNAse P as an internal control.	52153	1x10⁶ cp/mL 250μL

SARS-CoV-2 Panel Sequence

Target	Size	Sequence
N	1105	GAACAAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAAC CAGAATGGAGAACGCAGTGGGGCGCGATCAAAACAACGTCGGCCCCAAGGTTTACCCAATAATACTGCGTCTTGGTTCACCGCTCTCACTCAA CATGGCAAGGAAGACCTTAAATTCCCTCGAGGACAAGGCGTTCCAATTAACACCAATAGCAGTCCAGATGACCAAATTGGCTACTACCGAAGA GCTACCAGACGAATTCGTGGTGGTGACGGTAAAATGAAAGATCTCAGTCCAAGATGGTATTTCTACTACCTAGGAACTGGGCCAGAAGCTGGA CTTCCCTATGGTGCTAACAAAGACGGCATCATATGGGTTGCAACTGAGGGAGCCTTGAATACACCAAAAGATCACATTGGCACCCGCAATCCTG CTAACAATGCTGCAATCGTGCTACAACTTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAGAAGGGAGCAGAGGCGGCAGTCAAGCCT CTTCTCGTTCCTCATCACGTAGTCGCAACAGTTCAAGAAATTCAACTCCAGGCAGCAGTAGGGGAACTTCTCCTGCTAGAATGGCTGGCAATGG CGGTGATGCTGCTCTTGCTTTGCTGCTGCTTGACAGATTGAACCAGCTTGAGAGCAAAATGTCTGGTAAAGGCCAACAACAACAAGGCCAAACT GTCACTAAGAAATCTGCTGCTGAGGCTTCTAAGAAGCCTCGGCAAAAACGTACTGCCACTAAAGCATACAATGTAACACAAGCTTTCGGCAGAC GTGGTCCAGAACAAACCCAAGGAAATTTTGGGGACCAGGAACTAATCAGACAAGGAACTGATTACAAACATTGGCCGCAAATTGCACAATTTGC CCCCAGCGCTTCAGCGTTCTTCGGAATGTCGCGCATTGGCATGGAAGTCACACCTTCGGGAACGTG
E	193	TGTGCGTACTGCTGCAATATTGTTAACGTGAGTCTTGTAAAACCTTCTTTTTACGTTTACTCTCGTGTTAAAAATCTGAATTCTTCTAGAGTTCCT GATCTTCTGGTCTAAACGAACTAAATATTATATTAGTTTTTCTGTTTGGAACTTTAATTTTAGCCATGGCAGATTCCAACGGTACTATTACCGTTGA
RdRp	787	TGTAGAAAACCCTCACCTTATGGGTTGGGATTATCCTAAATGTGATAGAGCCATGCCTAACATGCTTAGAATTATGGCCTCACTTGTTCTTGC TCGCAAACATACAACGTGTTGTAGCTTGTCACACCGTTTCTATAGATTAGCTAATGAGTGTGCTCAAGTATTGAGTGAAATGGTCATGTGTGG CGGTTCACTATATGTTAAACCAGGTGGAACCTCATCAGGAGATGCCACAACTGCTTATGCTAATAGTGTTTTTAACATTTGTCAAGCTGTCACG GCCAATGTTAATGCACTTTTATCTACTGATGGTAACAAAATTGCCGATAAGTATGTCCGCAATTTACAACACAGACTTTATGAGTGTCTCTATAG AAATAGAGATGTTGACACAGACTTTGTGAATGAGTTTTACGCATATTTGCGTAAACATTTCTCAATGATGATACTCTCTGACGATGCTGTTGTGT GTTTCAATAGCACTTATGCAGTTGAACATGTTACCTTCTTCATCTACAATAAAATTGTTGATGAGCCTGAAGAACATGTCCAAATTCACACAATCG ACGGTTCATCCGGAGTTGTTAATCCAGTAATGGAACCAATTTATGATGAACCGACGACGACTACTAGCGTGCCTTTGTAAGCACAAGCTGATGA GTACGAACTTATGTACTCATTCGTTTCGGAAGAGACAGGTACGTTAATAGTTAATAGCGTACTTCTTTTTCTTGCTTTCGTGGTATTCTTGCTAGTT ACACTAGCCATCCTTACTGCGCTTCGATTG
ORF1	350	TGGTGCATCGTGTTGTCTGTACTGCCGTTGCCACATAGATCATCCAAATCCTAAAGGATTTTGTGACTTAAAAGGTAAGTATGTACAAATACCT ACAACTTGTGCTAATGACCCTGTGGGTTTTACACTTAAAAACACAGTCTGTACCGTCTGCGGTATGTGGAAAGGTTATGGCTGTAGTTGTGAT CAACTCCGCGAACCCATGCTTCAGTCAGCTGATGCACAATCGTTTTTAAACGGGTTTGCGGTGTAAGTGCAGCCCGTCTTACACCGTGCGGCA CAGGCACTAGTACTGATGTCGTATACAGGGCTTTTGACATCTACAATGATAAAGTAGCTGGTTTTGCTAA
RNP	119	GCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACTTGTGGAGACAGCCGCTCACCTTGGCTATTCAA AATCCCCTTGCTACTGCTGATCACGCGT

Download Armored RNA Quant^® SARS-CoV-2 Panel PDF

SARS-CoV-2 Spike Variants

Description	Part #	Configuration
Targets mutations in the SARS CoV-2 spike protein prevalent in the Alpha (B.1.1.7), Beta (B.1.351), Gamma (B.1.1.28), Delta (B.1.617.2), and Omicron (B.1.1.529) strains.	52160/52154	1x10⁶ cp/mL 250μL

SARS-CoV-2 SV1 Sequence

Target	Size	Sequence
	1877	CCCCCTGCATACACTAATTCTTTCACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTTAC CTTTCTTTTCCAATGTTACTTGGTTCCATGCTAT[ACATGTdel]CTCTGGGACCAATGGTACTAAGAGGTTTGATAACCCTGTCCTACCATTTAATG ATGGTGTTTATTTTGCTTCCACTGAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTG TTAATAACGCTACTAATGTTGTTATTAAAGTCTGTGAATTTCAATTTTGTAATGATCCATTTTTGGGTGTTTATTACCACAAAAACAACAAAAGTTG GATGGAAAGTGAGTTCAGAGTTTATTCTAGTGCGAATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACCTTGAAGGAAAACAGG GTAATTTCAAAAATCTTAGGGAATTTGTGTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACACGCCTATTAATTTAGTGCGTGATCT CCCTCAGGGTTTTTCGGCTTTAGAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACTTGCTTTACATAGAAGTTA TTTGACTCCTGGTGATTCTTCTTCAGGTTGGACAGCTGGTGCTGCAGCTTATTATGTGGGTTATCTTCAACCTAGGACTTTTCTATTAAAATATAA TGAAAATGGAACCATTACAGATGCTGTAGACTGTGCACTTGACCCTCTCTCAGAAACAAAGTGTACGTTGAAATCCTTCACTGTAGAAAAAGGAA TCTATCAAACTTCTAACTTTAGAGTCCAACCAACAGAATCTATTGTTAGATTTCCTAATATTACAAACTTGTGCCCTTTTGGTGAAGTTTTTAACGCC ACCAGATTTGCATCTGTTTATGCTTGGAACAGGAAGAGAATCAGCAACTGTGTTGCTGATTATTCTGTCCTATATAATTCCGCATCATTTTCCACTT TTAAGTGTTATGGAGTGTCTCCTACTAAATTAAATGATCTCTGCTTTACTAATGTCTATGCAGATTCATTTGTAATTAGAGGTGATGAAGTCAGACA AATCGCTCCAGGGCAAACTGGAAAGATTGCTGATTATAATTATAAATTACCAGATGATTTTACAGGCTGCGTTATAGCTTGGAATTCTAACAATCTT GATTCTAAGGTTGGTGGTAATTATAATTACCGGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGATATTTCAACTGAAATCTATC AGGCCGGTAGCACACCTTGTAATGGTGTTAAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTTATGGTGTTGGTTACCA ACCATACAGAGTAGTAGTACTTTCTTTTGAACTTCTACATGCACCAGCAACTGTTTGTGGACCTAAAAAGTCTACTAATTTGGTTAAAAACAAATGT GTCAATTTCAACTTCAATGGTTTAACAGGCACAGGTGTTCTTACTGAGTCTAACAAAAAGTTTCTGCCTTTCCAACAATTTGGCAGAGACATTGCT GACACTACTGATGCTGTCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCATGTTCTTTTGGTGGTGTCAGTGTTATAACACCAGGAACA AATACTTCTAACCAGGTTGCTGTTCTTTATCAGGGTGTTAACTGCACAGAAGTCCCTGTTGCTATTCATGCAGATCAACTTACTCCTACTTGGCGTG TTTATTCTACAGGTTCTAATGTTTTTCAAACACGTGCAGGC

SARS-CoV-2 SV2 Sequence

Target	Size	Sequence
N	1877	CCCCCTGCATACACTAATTCTTTCACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTT ACCTTTCTTTTCCAATGTTACTTGGTTCCATGCTAT[ACATGTdel]CTCTGGGACCAATGGTACTAAGAGGTTTGATAACCCTGTCCTACCATTT AATGATGGTGTTTATTTTGCTTCCACTGAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTAC TTATTGTTAATAACGCTACTAATGTTGTTATTAAAGTCTGTGAATTTCAATTTTGTAATGATCCATTTTTGGGTGTTTATTACCACAAAAACAACA AAAGTTGGATGGAAAGTGAGTTCAGAGTTTATTCTAGTGCGAATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACCTTGAAGG AAAACAGGGTAATTTCAAAAATCTTAGGGAATTTGTGTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACACGCCTATTAATTTAG TGCGTGATCTCCCTCAGGGTTTTTCGGCTTTAGAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACTTGCTTTA CATAGAAGTTATTTGACTCCTGGTGATTCTTCTTCAGGTTGGACAGCTGGTGCTGCAGCTTATTATGTGGGTTATCTTCAACCTAGGACTTTTC TATTAAAATATAATGAAAATGGAACCATTACAGATGCTGTAGACTGTGCACTTGACCCTCTCTCAGAAACAAAGTGTACGTTGAAATCCTTCAC TGTAGAAAAAGGAATCTATCAAACTTCTAACTTTAGAGTCCAACCAACAGAATCTATTGTTAGATTTCCTAATATTACAAACTTGTGCCCTTTTG GTGAAGTTTTTAACGCCACCAGATTTGCATCTGTTTATGCTTGGAACAGGAAGAGAATCAGCAACTGTGTTGCTGATTATTCTGTCCTATATAA TTCCGCATCATTTTCCACTTTTAAGTGTTATGGAGTGTCTCCTACTAAATTAAATGATCTCTGCTTTACTAATGTCTATGCAGATTCATTTGTAAT TAGAGGTGATGAAGTCAGACAAATCGCTCCAGGGCAAACTGGAAAGATTGCTGATTATAATTATAAATTACCAGATGATTTTACAGGCTGCGT TATAGCTTGGAATTCTAACAATCTTGATTCTAAGGTTGGTGGTAATTATAATTACCGGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTG AGAGAGATATTTCAACTGAAATCTATCAGGCCGGTAGCACACCTTGTAATGGTGTTAAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGT TTCCAACCCACTTATGGTGTTGGTTACCAACCATACAGAGTAGTAGTACTTTCTTTTGAACTTCTACATGCACCAGCAACTGTTTGTGGACCTAA AAAGTCTACTAATTTGGTTAAAAACAAATGTGTCAATTTCAACTTCAATGGTTTAACAGGCACAGGTGTTCTTACTGAGTCTAACAAAAAGTTTCT GCCTTTCCAACAATTTGGCAGAGACATTGCTGACACTACTGATGCTGTCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCATGTTCTT TTGGTGGTGTCAGTGTTATAACACCAGGAACAAATACTTCTAACCAGGTTGCTGTTCTTTATCAGGGTGTTAACTGCACAGAAGTCCCTGTTGCT ATTCATGCAGATCAACTTACTCCTACTTGGCGTGTTTATTCTACAGGTTCTAATGTTTTTCAAACACGTGCAGGC

Download Armored RNA Quant^® SARS-CoV-2 Spike Variants PDF

Respiratory Triplex

Description	Part #	Configuration
Contains regions of SARS-Cov-2, Influenza A (H1N1, H3N2, and H7N9), Influenza B, Respiratory Syncytial Virus A (RSVA), Respiratory Syncytial Virus B (RSVB), and RPP30 as an internal control.	52108	1x10⁸ cp/mL 250μL

Respiratory Triplex Sequence

Target	Size	Sequence
CoV-2	1001	GAACAAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAA CCAGAATGGAGAACGCAGTGGGGCGCGATCAAAACAACGTCGGCCCCAAGGTTTACCCAATAATACTGCGTCTTGGTTCACCGCTCTCACT CAACATGGCAAGGAAGACCTTAAATTCCCTCGAGGACAAGGCGTTCCAATTAACACCAATAGCAGTCCAGATGACCAAATTGGCTACTACCG AAGAGCTACCAGACGAATTCGTGGTGGTGACGGTAAAATGAAAGATCTCAGTCCAAGATGGTATTTCTACTACCTAGGAACTGGGCCAGAA GCTGGACTTCCCTATGGTGCTAACAAAGACGGCATCATATGGGTTGCAACTGAGGGAGCCTTGAATACACCAAAAGATCACATTGGCACCC GCAATCCTGCTAACAATGCTGCAATCGTGCTACAACTTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAGAAGGGAGCAGAGGCGG CAGTCAAGCCTCTTCTCGTTCCTCATCACGTAGTCGCAACAGTTCAAGAAATTCAACTCCAGGCAGCAGTAGGGGAACTTCTCCTGCTAGAAT GGCTGGCAATGGCGGTGATGCTGCTCTTGCTTTGCTGCTGCTTGACAGATTGAACCAGCTTGAGAGCAAAATGTCTGGTAAAGGCCAACAAC AACAAGGCCAAACTGTCACTAAGAAATCTGCTGCTGAGGCTTCTAAGAAGCCTCGGCAAAAACGTACTGCCACTAAAGCATACAATGTAACAC AAGCTTTCGGCAGACGTGGTCCAGAACAAACCCAAGGAAATTTTGGGGACCAGGAACTAATCAGACAAGGAACTGATTACAAACATTGGCCG CAAATTGCACAATTTGCCCCCAGCGCTTCAGCGTTCTTCGGAATGTCGCGCATTGGCATGGAAGTCACACCTTCGGGAACGTG
Flu	1430	ACGCGTGATCAGCAGAAGCAGGGGTTTAATTCTCATGGAATGGCTAAAGACAAGACCAATCTTGTCACCTCTGACTAAGGGAATTTTAGGA TTTGTGTTCACGCTCACCGTGCCCAGTGAGCGAGGACTGCAGCGTAGACGCTTTATCCAAAATGCCCTAAATGGAAATGGGGACCCGAACA ACATGGATAGAGCAGTTAAACTATACAAGAAGCTCAAAAGAGAAATAACATTCCATGGGGCCAAGGAGGTGTCACTAAGCTATTCAACTGGT GCACTTGCAAGTTGCATGGGCCTCATATACAACAGAATGGGAACAGGCCTGCTTGTGTGTATGGGCTTGCAGTAGCAAGTGGCCATGACTTT GAAAGGGAAGGGTACTCACTGGTCGGGATAGACCCATTCAAATTACTCCAAAACAGTCAAGTGGTCAGCCTGATGAGACCAAATGAAAATCC AGCTCACAAGAGTCAATTGGTATGGATGGCATCAACTTGTCAGACAGCCGAGGGTGCTATAAACACCAGCCTCCCATTTCAGAATGTACATCC GGTCACAATTGGGAAATGTCCAAAGTATGTAAAAAGCACAAAATTGAGGCTGGCCACAGGATTGAGGAATGTCCCGTCTATTCAATCTAGAGG CCTATTCTGAATGCATCACTCCAAATGGAAGCATTCCCAATGACAAACCATTCCAAAATGTAAACAGGATCACATACGGGGCCTGTCCCAGATA TGTTAAGCATAGCACTCTGAAATTGGCAACAGGAATGAGAAATATACCAGAGAAACAAACTAGGGGCATATTTGGCGCAATAGCGGGTTTCAT AGAAAATGGGGTATGGTTTCAGACACCAGAATGCACAGGGAGAGGGAACTGCTGCAGATTACAAAAGCACTCAATCGGCAATTGATCAAATA ACAGGGAAATTAAACCGGCTTATAGCAAAAACCAACCAACAATTTAAGTTGATAGACAATGAATTCAATGAGGTAGAGAAGCAAATCGGTAATG TGATAAATTGGACCAGAGATTCTATAACAGAAGTATGGTCATACAATGCTGAACTCTTGGTGGCAATGGAGAACCAGCATACAATTGAGAGGAT GAAGAAGATGGCCATCGGATCCTCAACTCACTCTTCGAGCGTCTCAATGAAGGACATTCAAAGCCAATTCGAGCAGCTGAAACTGCGGTGGGA GTCTTATCCCAATTTGGTCAAGAGCACCGATTATCACCAGAAGAGGGAGACCAATGGTTTTGTGCTCGGCAGATGGGAGAGATGGTGTGGAGA TATAAAGACCACAATTATGCCTGAAATTGACTCGATGGAAAAAGATATTGCCCTCTCTAGGGAGAGACTTGACCTGGGAGAGGATGCCCCTGAC GAAACCGACAACTCACCAATTCCTTTTTCCAATGATGGC
RSVA	589	CCTGTGAATATGGGAGGTTTCATCAAATGTATCTCATTAAGCTTAGGTATGAGAATAATTCTGTTAGGACATACATTAGTAAATTGTTCTACTAC TGACATTAAACTAAGGCCAAAGCTTATACAGTTTTGGAATACTATGTCAATATCTTCATCACCATACTTTTCTGTTAATATGCGATTAATAGGGCT AGTGTCAAAGTGATAATTTGTTGTTCTATAAGCTGGTATTGATGCAGGGAATTCACATGGTCTACTACTGACTGTAAGGCGATGCAAATAATTG ACACTTAAATATTGTGGAAATAATTTCTTGGCCTTTTCATATGTTAACCCAAGGGTTCCTATGCTGAGTTCTTCCATGAATTCATCCTTGTTATCTA TAGATGCATACACCCAATCCAATTTTGCTAATAGATCTATTTGATCTCTCTGTTTTTTTGGTTAAGACTTGTCTATTATAAACTGGCATTGTTTTTTT CTCTTGTGTAGATGAACCAACCCATGGTTTAGTGGGTCCTCTCTCACCACGTGTTAAACTGTTAACATTATATTTCTCTATAATTATGCCACTAGA TATAGTGCTTGTA
RSVB	383	TGATGATTTTTGATCAGTGATCAACTCACTCAGCAATCAACAACATCAATAAAACAGACACCAATCCATTGAATCAATTGCCAGACTGAAAAAA CAAACATCCATCAGCAGAACCACCAACCAATCAATCAACCAATTGATCAATCAGCACCCTGACAAAATTAACAATATAGTAACAAAAAAAGAAC AAGATGGGGCAAATATGGAAACATACGTGAACAAGCTTCACGAAGGCTCCACATACACAGCAGCTGTTCAGTACAATGTTCTAGAAAAAGAT GATGATCCCGCATCACTAACAATATGGGTGCCTATGTTCCAGTCATCTGTGCCAGCAGACTTGCTCATAAAAGAACTTGCAAGCATCAACATA CTGGTAAAGC
RNP	119	GCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACTTGTGGAGACAGCCGCTCACCTTGGCTATT CAAAATCCCCTTGCTACTGCTGATCACGCGT

Download Armored RNA Quant^® Respiratory Triplex Control PDF

Armored RNA Quant^® EPA 1615 Controls

Description	Part #	Configuration
Contains sequences detected by the Enterovirus, Norwalk GI, and Norwalk GII virus assays described in EPA Method 1615 - Measurement of Enterovirus and Norovirus occurrence in water by culture and RT-qPCR.	52000	1x10¹² cp/mL 500μL

EPA 1615 Sequence

Target	Size	Sequence
Nor-1	96	G CCATGTTCCGCTGGATGCGCTTCCATGACCTCGGATTGTGGACAGGAGATCGCGATCTTCTGCCCGAATTCGTAAATGATGATGGCGTCTAAGG
Nor-2	91	A ATGTTCAGATGGATGAGATTCTCAGATCTGAGCACGTGGGAGGGCGATCGCAATCTGGCTCCCAGCTTTGTGAATGAAGATGGCGTCGA
EV	196	C CTCCGGCCCCTGAATGCGGCTAATCCCAACCTCGGGGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCGCAAGTCCGTGGCGGAA CCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATTGTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAAGCGAATTGGATTGGCCATC CGGT

Download Armored RNA Quant^® EPA 1615 Controls PDF

Enterovirus

Description	Part #	Configuration
Contains sequences amplified by primer binding regions for polio virus (type I Sabin), coxsackievirus A and coxsackievirus B (Schwab, et al., 1995 and Rotbart, 1990).	42102	5x10⁵ cp/mL 5x100μL

Enterovirus Sequence

Target	Size	Sequence
	263	TGAGCTACATAAGAATCCTCCGGCCCCTGAATGCGGCTAATCCCAACCTCGGGGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCGC AAGTCCGTGGCGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATTGTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAAGCG AATTGGATTGGCCATCCGGTGAAAGTGAGATTCATTATCTATCTGTTTGCTGGATTCGCTCCATTGAGTGTG

Download Enterovirus PDF

Pentavalent Arbovirus Control

(CHIKV,DENV,WNV,YFV,ZIKV)

Description	Part #	Configuration
Targets regions of the Chikungunya, Dengue, West Nile, Yellow Fever, and Zika viruses.	49659	1x10⁸ cp/mL 500μL

Pentavalent Arbovirus Control Sequence

Target	Size	Sequence
	2200	CCGACTCAACCATCCTGGATTTGCCAGCAAGGAGGATGATGTCGGACAGGAAGTACCACTGCGTCTGCCTTCATCTGCACCCAAGTGTACCATT GCGGTGTACACTGCCTGTGACCGCTTCATTACGAAGGCAAAATGCGCTTGAGCATATGGTTACGCAGATAGTTACGAGTCATCTGCGTATTGGG ACGCATTGAAACCACCATGTGTCACCAGCATTTGTACTGGCAGCAGCCACGTTAACGTCACACAGATGAGTTGAATTTGCTGCCAGCCCTATTTC GAAAAGGAACCGGAGGAAACCCTACGCATGCTTGATTAACGTCATGAGACCTGGGTACTATCTTAAGCTCCGCGTCCTTTACCAAGTTCCAATGT CTTCAGCCTGGACACCTTTTTAGGAAGACCAGGACAATTTGGTTGTCACATACCACCCTCGTTGGGACTGGTTGTTGCTGTTGCCGCTTAGGTAT ATGTGTCCCCTAAGAGACATTCAGATCTCTGATGAACAACCAACGTTATATGCTGAAACGCGCGAGTTGTTGGCGAAGAGATTCTCAAATTCAAA AGGAAGTCGTGCAATATTCATGTGGCTGGGAGCACGCTTGTTTAGTAGAGAGAATTCACTCAGTTGACTAGTGGTTAGAGGAGACCCCTCCCTT AAGGACTAGAGGTTAGAGGAGACCCCCTTACAGCATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCTACAGCATCATTCCAGGCACA GAACGCCAGAAAATGGAATGGTTTAGTAGTTCGCCTGTGTGAGCTGACAAACTTAGTAGTGTTTGTGAGGATTTTTGCGAGCTGTTTCTTAGCAC GAAGATCTCGATGTCTAAGAAACCAGGAGGGCTTGGCTGTCAATATGCTAAAACGCTTCTACCGTCAGCGATCTCTTCATGGGAGAAGCTCACTT CAAACGTGCTGACCCAGTTCCTTTTCAGTTGGGCCTTCTGGTCGTGTTCTTCCACCCAGGAGGTCCTTCGCAAGAGGTGGACAGCCAAGATCAGC ATGCCAGCTTTTGGGGGCATTACTTACACTGTTCGCTGTCCCTGTGAATTGTTTGGTCCATCCATGCAGGAGGAGAGTTGTCTGGAACCGTGTTTG GTTCCACCGGAAGTTGAGTAGACGGTGCTGCCTGCGACTCAACCCCAGGAGGACTGGGTGAACAAATTCCATGTAAGCCCTCAGAACCGTCTCG GAAGGTTGCTAATTGAGGTGCATTGGTCTGCAAATCGAGTTGCTAGGCAATAAACACTTATCGTTCGTTGAGCGATTAGCAGAGAACTGACTTTCT GGTCGTAAAGCTCAGGGATTACAACATGATGGGGAAAAGAGAGAATTTGGTACATGTGGCTGGGAGCTTCGCGGATGACACCGCTGGATGGGA CACGTGCACGGATGTGACAGACTGAAAATTCGATTGTGTTGTCCGGCCCATCGATGACAGGTTCGGCCTGGTTTGGTCATGATACTGCTGATTGC CCCGGCATATAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAG CAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGTTTGGCAAAGGGAGCCTGGTGTAAGTTTGCATGCTCCAAGAAAATTACCGGGAAG AGCATCCAGCCAGATATCTGGAGTACCGGATAATGCTGTCAACCACTGCAAGCGGAAGGTTATGGTGCTGCAGGGAGTGCACAATGCCCCCACT GTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCATCTGTGGCATGAACCCAATAGTCCTTTGCAGCTGGAGCGTGGTG GAGTGGTGCTCTATGGGATTCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTTGGAGAAAAAGATGGGACAGGTGTTACGCTC AGAGTCCTCTCCATGTTTGTGCCCATACACCAGTTGATGGAAACCCTGGAGCGACTTAAGTACACATACCAAAACAAAGTGGTTTCTTAGACCAGC TGAAATTCAAGACCAAAGGGGGAGCGGATCTCAATGTTGTCAGGCCTGCTAGTCAGCCACAGTTTGGGGAAAGCTGTGCAGCCTGTAACCCCCC CAGGAGAAGCTGGGAAATCAAGCTC

Download the Pentavalent Arbovirus Control PDF

Zika Virus

Description	Part #	Configuration
Targets regions of the Zika virus.	49610	5x10⁵ cp/mL 500μL

Zika Virus Sequence

Target	Size	Sequence
	2164	GCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGTGCATAGGAGTCA GCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATATTGTCTTGGAACATGGAGGTTGTGTCACCGTAATGGCACAGGA CAAACCGCATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCCAACACAAGGTGAAGC CTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAG GGAGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCT GTCAGTTCACTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAG TGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCA AAGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGA GAGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCCAGGCACTAAGGTCCACGTGG AGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCACAAT GCCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCAGAAAGCAACTTAGTAAGGTCAA TGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAA TGACCACAAAGATCATCCTGTGGCATGAACCCAATAGCCATACCCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGT GGTGCTCTATGGGATCAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAA GAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACC ATAAAAAGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGATGTGAATCTCGG CTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGA AACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCCACACAAGGGTCAGCGTCCTCTCTAATA AACGGGGTTGTCAGGCTCCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAA AGAGTTTTCAAGGAAAAAGTGGACACTAGGGTGCCAGACCCCCAAGGTTCGAAGCCCTTGGATTCTTGAACGAGGATCACTGGATGGGGAGAG AGAACTCAGGAGGTGGTGTTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATG CAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACCAACCAAATGGAGAAAGGGCACAGGG CCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAAACAGTTATGGACATTATT TCGAGACAAGACCAAAGGGGGAGCGGACAAGTTGTCAC

Internal Process Control (Armored RNA Quant)

Description	Part #	Configuration
Targets a non-specific, 1,000 nucleotides in vitro transcribed RNA (non-homologous) sequence intended to be used as a spike-in to sample (e.g., urine, blood, CSF, plasma/liquid biopsy) to monitor the overall efficiency of a testing process.	49650	2x10⁶ cp/mL 500μL

Internal Process Control Sequence

Target	Size	Sequence
	1000	GTACTGACGTAAAGTCACTATTTTTCGTGCAACGTACGTCTCGATGTACAACTGCTCTATTACGGTTCATTTTTTTTGTAGGGTTACGCGGCCA GATGACTCCATCTTATCCCCTTGAAAACATTCTTATTTGTACGCCATAGTGGCATCGCGGTTGGATATCAATCGTATTGGACGCAAGCGCGCT CTACTCAGTTTATAAGACCGCCAACTATTTTCGCAAGATCAGTGTATTTACGCTGACTCCAGTGGTGAAACTCCTAAGATCTGTTTAGCTATTG CGCCGTGCGTTTATCAAATCGGGCTTCCCAACATTCATTCTTAGAAGGAAGCTCGATAGTTCAGAGCTGCGGAAGGCCCAATTTCATATTATA TGTATGAGCCTGTCAATACCTGCACCCACGAACACCACAGTGACTAGAGTATGAGAGGTCGACGATCTACGGATGGTGATGAGCACGGAGAT CTAAGCGTGGAAGTGGCTATATAGAGCAGATATATTATATGACGTACCAGAGGATCACCTACTAAAAGACTTTTCGAGAATCTACACCTACTAG CAAGGGTAGCCGATTAGTGGATCATCTAAGACATCAAGGCTCAAACTAATTTTACCATGGACGCTGCATTTACGCTTGCACATTTTATGTTGGCA GCCTTTGCCGCGGCACATAGCGATATCCCGTACCCGCTTTTCTTTAAGTTAATCGCCGATGATTGGCTCAATAATCGCCTCACTTGTGCGATGAC TAGCCAGGCGTTTCCCGCGTTTCTAGATATTATCGCGCTTATATAGTATAGACGAGTACCCTTTGTTGTTATTGCAGCACCCAACAGAACTAAGTA ATCTTTAGGCTGCGGCCGCTTAGGTGGCAGAAGATTTGCTCGATGTTCTCAAGTAAAGGACGTCGGGGAGTTGACGGTTGGCAGGTAACGTATG GATCTTTAATATAATCTAGGCAACAAGTAAGGGCCATTGAGCGCTTATATGCCGCAGTCT

Download the Internal Process Control PDF

RNase P

Description	Part #	Configuration
Targets the human RNase P gene; often used as an internal control because abundant copies in the human genome make it readily detectable.	52152	1x10⁶ cp/mL 500μL

RNase P Sequence

Target	Size	Sequence
	144	GAATTCGGCACGAGGTGGGACTTCAGCATGGCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACTT GTGGAGACAGCCGCTCACCTTGGCTATTCAGTTGTTGCTATCAATCATATCGTT

Armored DNA Quant^™

Armored DNA technology stabilizes and protects nucleic acids from nuclease degradation by packaging them in a protective protein coat. Encapsulated as non-infectious, nuclease-resistant, pseudo-viral particle.

Mpox Nonvariola Orthopox Control

Description	Part #	Configuration
A single, concatenated construct of both nonvariola Orthopox and Mpox-specific sequence blended with with RNAse P to allow for an all-in-one process control. The control is provided as two tubes of high and low concentration along with diluent for convenience.	49670	500μL

Mpox Nonvariola Orthopox Control Sequence

Target	Size	Sequence
NVO/MPX	300	ATAATAAACGGAAGAGATATAGCACCACATGCACCATCCAATGGAAAATGTAAAGACAACGAATACAGAAGCCGTAATCTATGTTGTCTAT CGTGTCCTCCGGGAACTTACGCTTCCAGATTATGTGATAGCAAGACTAATACACAATGTACGCCTAAAACAGGCTACCAGTTCAACTGAAA AGGCCATCTATGATTCCATGCAATATACGTACAAGATAGTAGCCAACTCAGTATATGGTCTGATGGGATTTAGAAATAGTGCTCTATACTCA TACGCTTCGGCTAAGAGTTGCACATC
RNP	144	GAATTCGGCACGAGGTGGGACTTCAGCATGGCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACT TGTGGAGACAGCCGCTCACCTTGGCTATTCAGTTGTTGCTATCAATCATATCGTT

Download the Mpox/Nonvariola Orthopox Control PDF

Internal Process Control (Armored DNA Quant)

Description	Part #	Configuration
Targets a non-specific, 495 base pair in vitro transcribed DNA (non-homologous) sequence intended to be used as a spike-in to sample (e.g., urine, blood, CSF, plasma/liquid biopsy) to monitor the overall efficiency of a testing process.	52003	1x10⁸ cp/mL 500μL

Internal Process Control Sequence

Target	Size	Sequence
	495	GACATCAAGGCTCAAACTAATTTTACCATGGACGCTGCATTTACGCTTGCACATTTTATGTTGGCAGCCTTTGCCGCGGCACATAGCGATATCC CGTACCCGCTTTTCTTTAAGTTAATCGCCGATGATTGGCTCAATAATCGCCTCACTTGTGCGATGACTAGCCAGGCGTTTCCCGCGTTTCTAGA TATTATCGCGCTTATATAGTATAGACGAGTACCCTTTGTTGTTATTGCAGCACCCAACAGAACTAAGTAATCTTTAGGCTGCGGCCGCTTAGGTG GCAGAAGATTTGCTCGATGTTCTCAAGTAAAGGACGTCGGGGAGTTGACGGTTGGCAGGTAACGTATGGATCTTTAATATAATCTAGGCAACA AGTAAGGGCCATTGAGCGCTTATATGCCGCAGTCTAAACATGAGGATTACCCATGTAAGCTTATTCCCTTTAGTGAGGGTTAATTTTAGCTTGGC ACTGGCCGTCGTTTTACAACGTCG

Request A Quote

Armored RNA^®

Hepatitis G Virus

Description	Part #	Configuration
Contains sequences amplified by primer binding regions for Hepatitis G Virus (Schlueter, 1996); the PCR product generated is 185 nucleotides.	42024	250μL

Hepatitis G Virus Sequence

Target	Size	Sequence
	263	CCGGCACTGGGTGCAAGCCCCAGAAACCGACGCCTATTTTAAACAGACGTTATGAACCGGCGCTGACTCGGCGACCGGCCAAAAGGTGGTGG ATGGGTGATGCCAGGGTTGGTAGGTCGTAAATCCCGGTCATCTTGGTAGCCACTATAGGTGGGTCTTAAGGGTTAGTCAAGGTCCCTCTGGCG CTTGTGGCGAGAAGCGCACGGTCCACAGGTGTTGGCCCTACCGGTGTGAATAAGGGCCCGACGTCAGGCTCGTCGTTAAACCGAGCCCATTA CCCACCTGGGCAAACGACGCCCACGTACGGTCCACGTCGCCCTTCAATGTCTCTCTTGACCAATAGGCTTAGCCGGCGAGTTGACAAGGACCA

Download the Hepatitis G Virus PDF

Enterovirus

Description	Part #	Configuration
Contains sequences amplified by primer binding regions for polio virus (type I Sabin), coxsackievirus A and coxsackievirus B (Schwab, et al., 1995 and Rotbart, 1990).	42050	250μL

Enterovirus Sequence

Target	Size	Sequence
	263	TGAGCTACATAAGAATCCTCCGGCCCCTGAATGCGGCTAATCCCAACCTCGGGGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCG CAAGTCCGTGGCGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATTGTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAA GCGAATTGGATTGGCCATCCGGTGAAAGTGAGATTCATTATCTATCTGTTTGCTGGATTCGCTCCATTGAGTGTG

Download the Enterovirus PDF

Request A Quote

Armored RNA Quant Made-to-Order

Bacteriophage MS2

Description	Part #	Configuration
Bacteriophage MS2	52223

Beta-Actin (ACTB)

Description	Part #	Configuration
Beta-Actin (ACTB)	52225

Ebolavirus

Description	Part #	Configuration
Ebolavirus	52217

Glucuronidase Beta (GUSB)

Description	Part #	Configuration
Glucuronidase Beta (GUSB)	52224

Hepatitis C Virus (GT 2b)

Description	Part #	Configuration
Hepatitis C Virus (GT 2b)	42101

Download the Hepatitis C Virus (GT 2b) PDF

Hepatitis D Virus

Description	Part #	Configuration
Hepatitis D Virus	52212

HIV (Subtype B)

Description	Part #	Configuration
HIV (Subtype B)	42103

Human Papillomavirus 16

Description	Part #	Configuration
Human Papillomavirus 16	52219

Human Papillomavirus 18

Description	Part #	Configuration
Human Papillomavirus 18	52220

Sapovirus I, II, IV

Description	Part #	Configuration
Sapovirus I, II, IV	52221

Sapovirus V

Description	Part #	Configuration
Sapovirus V	52222

Sudan Ebolavirus

Description	Part #	Configuration
Sudan Ebolavirus	52218

Request A Quote

Armored RNA^® Made-to-Order

Dengue Virus (Type I)

Description	Part #	Configuration
Dengue Virus (Type I)	42044

Hepatitis C Virus (GT 1a)

Description	Part #	Configuration
Hepatitis C Virus (GT 1a)	42004

Hepatitis C Virus (GT 1b)

Description	Part #	Configuration
Hepatitis C Virus (GT 1b)	42006

Hepatitis C Virus (GT 2a/c)

Description	Part #	Configuration
Hepatitis C Virus (GT 2a/c)	42008

Hepatitis C Virus (GT 2b)

Description	Part #	Configuration
Hepatitis C Virus (GT 2b)	42010

Hepatitis C Virus (GT 3a)

Description	Part #	Configuration
Hepatitis C Virus (GT 3a)	42012

HIV (Subtype B)

Description	Part #	Configuration
HIV (Subtype B)	42000

Norovirus GI

Description	Part #	Configuration
Norovirus GI	42030

Norovirus GII

Description	Part #	Configuration
Norovirus GII	42032

SARS (BNI-1)

Description	Part #	Configuration
SARS (BNI-1)	42090

SARS (CoV-NC)

Description	Part #	Configuration
SARS (CoV-NC)	42091

West Nile Virus (Cap)

Description	Part #	Configuration
West Nile Virus (Cap)	42042

West Nile Virus (HNY1999)

Description	Part #	Configuration
West Nile Virus (HNY1999)	42040

West Nile Virus (NEN)

Description	Part #	Configuration
West Nile Virus (NEN)	42041

Request More Information

Molecular Assay Reagents

RNARetain Buffer

Description	Part #	Configuration
Intended for the collection, storage, and transportation of fresh tissue specimens for subsequent RNA isolation and further molecular testing. Eliminates the need to immediately process specimens, enabling RNA extraction and molecular testing at a later time and/or transport to a different location.	49536	Volume 2L^†

^†Variable concentrations, volumes and vial quantities available upon request

TSMIII Buffer

Description	Part #	Configuration
A buffered solution ideally suited for the dilution of Armored products. The additives provide stability to the protein-coated nucleic acid through multiple freeze-thaws when stored properly, allowing for more flexible and scalable testing processes.	49600	Volume 50mL

Request More Information

Armored Molecular Quality Controls Catalog

What is Armored RNA Technology?

Catalog of Armored RNA and Armored DNA Products

Armored RNA Quant®

SARS-CoV-2

SARS-CoV-2 Sequence

SARS-CoV-2 Panel

SARS-CoV-2 Panel Sequence

SARS-CoV-2 Spike Variants

SARS-CoV-2 SV1 Sequence

SARS-CoV-2 SV2 Sequence

Respiratory Triplex

Respiratory Triplex Sequence

Armored RNA Quant® EPA 1615 Controls

EPA 1615 Sequence

Enterovirus

Enterovirus Sequence

Pentavalent Arbovirus Control

(CHIKV,DENV,WNV,YFV,ZIKV)

Pentavalent Arbovirus Control Sequence

Zika Virus

Zika Virus Sequence

Internal Process Control (Armored RNA Quant)

Internal Process Control Sequence

RNase P

RNase P Sequence

Armored DNA Quant™

Mpox Nonvariola Orthopox Control

Mpox Nonvariola Orthopox Control Sequence

Internal Process Control (Armored DNA Quant)

Internal Process Control Sequence

Armored RNA®

Hepatitis G Virus

Hepatitis G Virus Sequence

Enterovirus

Enterovirus Sequence

Armored RNA Quant Made-to-Order

Bacteriophage MS2

Beta-Actin (ACTB)

Ebolavirus

Glucuronidase Beta (GUSB)

Hepatitis C Virus (GT 2b)

Hepatitis D Virus

HIV (Subtype B)

Human Papillomavirus 16

Human Papillomavirus 18

Sapovirus I, II, IV

Sapovirus V

Sudan Ebolavirus

Armored RNA® Made-to-Order

Dengue Virus (Type I)

Hepatitis C Virus (GT 1a)

Hepatitis C Virus (GT 1b)

Hepatitis C Virus (GT 2a/c)

Hepatitis C Virus (GT 2b)

Hepatitis C Virus (GT 3a)

HIV (Subtype B)

Norovirus GI

Norovirus GII

SARS (BNI-1)

SARS (CoV-NC)

West Nile Virus (Cap)

West Nile Virus (HNY1999)

West Nile Virus (NEN)

Molecular Assay Reagents

RNARetain Buffer

TSMIII Buffer

Order Armored Molecular Controls

Armored RNA Quant^®

Armored RNA Quant^® EPA 1615 Controls

Armored DNA Quant^™

Armored RNA^®

Armored RNA^® Made-to-Order